The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study - PubMed (original) (raw)
Affiliations
- PMID: 17542340
Clinical Trial
The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study
R Provenzano et al. Clin Nephrol. 2007 May.
Abstract
Aim: This study was designed to assess the potential of the continuous erythropoietin receptor activator (C.E.R.A.) to correct anemia at extended administration intervals in erythropoiesis-stimulating agent-naīve patients with chronic kidney disease (CKD) not on dialysis and to determine its optimal starting dose.
Methods: Patients were assigned to subcutaneous C.E.R.A. at 3 doses: 0.15, 0.30 and 0.60 microg/kg/wk. During the first 6 weeks, dose adjustments for efficacy were not permitted in order to assess dose response. Within each of the 3 dose groups, patients were randomized to receive C.E.R.A. QW, Q2W or Q3W; the total dose during the first 6 weeks was the same for a particular dose group across the frequency subgroups. During the next 12 weeks, dose was adjusted according to predefined hemoglobin (Hb) criteria. The primary efficacy parameter was change in Hb over 6 weeks, estimated from regression analysis between baseline and the point at which the patient received a dose change or blood transfusion. It therefore provided an estimate of Hb increase based on starting dose. Other endpoints included Hb response rate (proportion of patients with a Hb increase > 1.0 g/dl on 2 consecutive occasions). A 1-year extension period investigated long term tolerability and efficacy.
Results: A dose-dependent relationship was noted in the mean change in Hb from baseline over 6 weeks (p < 0.0001), independent of administration schedule (p = 0.9201). There was also a significant relationship between Hb change and median serum C.E.R.A. concentration (p < 0.0001). Erythropoietic responses were sustained in all groups with mean changes from baseline in Hb > 1.2 g/dl observed at doses > or = 0.30 microg/kg/wk. Hb response rate increased with increasing dose: 67, 72 and 90% with C.E.R.A. 0.15, 0.30 and 0.60 microg/kg/wk, respectively. Generally, the median Hb response time was faster with increasing dose (89, 43 and 31 days, respectively). Response was unrelated to administration frequency. Stable Hb concentrations were maintained throughout the 1-year extension period. C.E.R.A. was generally well tolerated, and the most common adverse events were hypertension, urinary tract infection and renal failure.
Conclusions: C.E.R.A. corrected anemia and maintained sustained and stable control of Hb over 1 year. These results suggest that 0.60 microg/kg subcutaneous C.E.R.A. given twice monthly is a suitable starting dose for further investigation in Phase III studies in patients with CKD not on dialysis.
Similar articles
- Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
Besarab A, Salifu MO, Lunde NM, Bansal V, Fishbane S, Dougherty FC, Beyer U; Ba16285 Study Investigators. Besarab A, et al. Clin Ther. 2007 Apr;29(4):626-39. doi: 10.1016/j.clinthera.2007.04.014. Clin Ther. 2007. PMID: 17617286 Clinical Trial. - Continuous Erythropoietin Receptor Activator (C.E.R.A.) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: a randomised, multicentre, multiple-dose, phase II study.
de Francisco AL, Sulowicz W, Klinger M, Niemczyk S, Vargemezis V, Metivier F, Dougherty FC, Oguey D; BA16260 Study Invesigators. de Francisco AL, et al. Int J Clin Pract. 2006 Dec;60(12):1687-96. doi: 10.1111/j.1742-1241.2006.01214.x. Int J Clin Pract. 2006. PMID: 17109676 Clinical Trial. - Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
Sulowicz W, Locatelli F, Ryckelynck JP, Balla J, Csiky B, Harris K, Ehrhard P, Beyer U; PROTOS Study Investigators. Sulowicz W, et al. Clin J Am Soc Nephrol. 2007 Jul;2(4):637-46. doi: 10.2215/CJN.03631006. Epub 2007 May 23. Clin J Am Soc Nephrol. 2007. PMID: 17699476 Clinical Trial. - The Primavera study protocol design: evaluating the effect of continuous erythropoiesis receptor activator (C.E.R.A.) on renal function in non-anemic patients with chronic kidney disease.
Fliser D, Dellanna F, Koch M, Seufert J, Witzke O, Hauser IA. Fliser D, et al. Contemp Clin Trials. 2011 Nov;32(6):786-92. doi: 10.1016/j.cct.2011.06.008. Epub 2011 Jul 7. Contemp Clin Trials. 2011. PMID: 21762788 Review. - Should the target hemoglobin for patients with chronic kidney disease treated with erythropoietic replacement therapy be changed?
Berns JS. Berns JS. Semin Dial. 2005 Jan-Feb;18(1):22-9. doi: 10.1111/j.1525-139X.2005.18105.x. Semin Dial. 2005. PMID: 15663760 Review.
Cited by
- Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis.
Chung EY, Palmer SC, Saglimbene VM, Craig JC, Tonelli M, Strippoli GF. Chung EY, et al. Cochrane Database Syst Rev. 2023 Feb 13;2(2):CD010590. doi: 10.1002/14651858.CD010590.pub3. Cochrane Database Syst Rev. 2023. PMID: 36791280 Free PMC article. Review. - Model-based approach for methoxy polyethylene glycol-epoetin beta drug development in paediatric patients with anaemia of chronic kidney disease.
Chanu P, Schaefer F, Warady BA, Schmitt CP, Reigner B, Schnetzler G, Meyer Reigner S, Eisner M, Weichert A, Frey N. Chanu P, et al. Br J Clin Pharmacol. 2020 Apr;86(4):801-811. doi: 10.1111/bcp.14186. Epub 2020 Jan 21. Br J Clin Pharmacol. 2020. PMID: 31770451 Free PMC article. - Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease.
Saglimbene VM, Palmer SC, Ruospo M, Natale P, Craig JC, Strippoli GF. Saglimbene VM, et al. Cochrane Database Syst Rev. 2017 Aug 7;8(8):CD009904. doi: 10.1002/14651858.CD009904.pub2. Cochrane Database Syst Rev. 2017. PMID: 28782299 Free PMC article. Review. - Subcutaneous C.E.R.A. for the Treatment of Chronic Renal Anemia in Predialysis Patients.
Üstündağ S, Doğan E, Duranay M, Kazancıoğlu R, Çelik V, Ünsal A, Altıntepe L, Dursun B, Akbaş E, Özdener F, Yıldız A. Üstündağ S, et al. Balkan Med J. 2016 May;33(3):322-30. doi: 10.5152/balkanmedj.2016.141173. Epub 2016 May 1. Balkan Med J. 2016. PMID: 27308077 Free PMC article. - Methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa for anemia in non-dialysis-dependent CKD: a systematic review.
Alsalimy N, Awaisu A. Alsalimy N, et al. Int J Clin Pharm. 2014 Dec;36(6):1115-25. doi: 10.1007/s11096-014-0023-x. Epub 2014 Oct 7. Int J Clin Pharm. 2014. PMID: 25288147 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical